AstraZeneca Reports Acquisition of Amolyt Pharma for ~$1.05B
Shots:
- AstraZeneca has signed a definitive agreement to acquire Amolyt Pharma to enhance its rare disease pipeline, Alexion, beyond complement inhibition
- As per the agreement, AstraZeneca will acquire all outstanding shares of Amolyt for a total of ~$1.05B (on cash & debt-free basis) which includes $800M upfront at closing plus an additional contingent of $250M on achieving specified regulatory milestone. The transaction is expected to close at the end of Q3’24
- The acquisition will further strengthen the company’s bone metabolism pipeline by adding Amolyt’s eneboparatide (AZP-3601), a PTH receptor 1 (PTHR1) agonist, currently under P-III clinical evaluation for the treatment of chronic hypoparathyroidism
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
